^
Association details:
| Biomarker: | KIT N820Y |
|---|---|
| Cancer: | Gastrointestinal Stromal Tumor |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood
Published date:
07/17/2020
Excerpt:
In two patients who achieved PR, one had a gastric GIST with KIT exon 11 V560D mutation and secondary exon 17 N820Y mutation, and the other had jejunum GIST with primary KIT exon 17 N822K mutation.
DOI:
10.1002/cam4.3319
